Copyright Reports & Markets. All rights reserved.

China Antidiabetic Biguanides Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Antidiabetic Biguanides Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Metformin IR Market Performance (Volume)
      • 2.1.2 Metformin SR Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Metformin IR Market Performance (Value)
      • 2.1.2 Metformin SR Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Hospitals Market Performance (Volume)
      • 3.1.2 Clinics Market Performance (Volume)
      • 3.1.3 Other Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Pfizer
      • 4.1.1 Pfizer Profiles
      • 4.1.2 Pfizer Product Information
      • 4.1.3 Pfizer Antidiabetic Biguanides Business Performance
      • 4.1.4 Pfizer Antidiabetic Biguanides Business Development and Market Status
    • 4.2 AstraZeneca
      • 4.2.1 AstraZeneca Profiles
      • 4.2.2 AstraZeneca Product Information
      • 4.2.3 AstraZeneca Antidiabetic Biguanides Business Performance
      • 4.2.4 AstraZeneca Antidiabetic Biguanides Business Development and Market Status
    • 4.3 GlaxoSmithKline
      • 4.3.1 GlaxoSmithKline Profiles
      • 4.3.2 GlaxoSmithKline Product Information
      • 4.3.3 GlaxoSmithKline Antidiabetic Biguanides Business Performance
      • 4.3.4 GlaxoSmithKline Antidiabetic Biguanides Business Development and Market Status
    • 4.4 Merck & Co
      • 4.4.1 Merck & Co Profiles
      • 4.4.2 Merck & Co Product Information
      • 4.4.3 Merck & Co Antidiabetic Biguanides Business Performance
      • 4.4.4 Merck & Co Antidiabetic Biguanides Business Development and Market Status
    • 4.5 Eli Lilly
      • 4.5.1 Eli Lilly Profiles
      • 4.5.2 Eli Lilly Product Information
      • 4.5.3 Eli Lilly Antidiabetic Biguanides Business Performance
      • 4.5.4 Eli Lilly Antidiabetic Biguanides Business Development and Market Status
    • 4.6 Sanofi
      • 4.6.1 Sanofi Profiles
      • 4.6.2 Sanofi Product Information
      • 4.6.3 Sanofi Antidiabetic Biguanides Business Performance
      • 4.6.4 Sanofi Antidiabetic Biguanides Business Development and Market Status
    • 4.7 Takeda Pharmaceuticals
      • 4.7.1 Takeda Pharmaceuticals Profiles
      • 4.7.2 Takeda Pharmaceuticals Product Information
      • 4.7.3 Takeda Pharmaceuticals Antidiabetic Biguanides Business Performance
      • 4.7.4 Takeda Pharmaceuticals Antidiabetic Biguanides Business Development and Market Status
    • 4.8 Novo Nordisk
      • 4.8.1 Novo Nordisk Profiles
      • 4.8.2 Novo Nordisk Product Information
      • 4.8.3 Novo Nordisk Antidiabetic Biguanides Business Performance
      • 4.8.4 Novo Nordisk Antidiabetic Biguanides Business Development and Market Status
    • 4.9 Servier Laboratories
      • 4.9.1 Servier Laboratories Profiles
      • 4.9.2 Servier Laboratories Product Information
      • 4.9.3 Servier Laboratories Antidiabetic Biguanides Business Performance
      • 4.9.4 Servier Laboratories Antidiabetic Biguanides Business Development and Market Status
    • 4.10 Boehringer Ingelheim
      • 4.10.1 Boehringer Ingelheim Profiles
      • 4.10.2 Boehringer Ingelheim Product Information
      • 4.10.3 Boehringer Ingelheim Antidiabetic Biguanides Business Performance
      • 4.10.4 Boehringer Ingelheim Antidiabetic Biguanides Business Development and Market Status
    • 4.11 Bristol-Myers Squibb

    5 Market Performance for Manufacturers

    • 5.1 China Antidiabetic Biguanides Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 China Antidiabetic Biguanides Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 China Antidiabetic Biguanides Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 China Antidiabetic Biguanides Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 South China Market Performance for Manufacturers
      • 6.1.1 South China Antidiabetic Biguanides Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 South China Antidiabetic Biguanides Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 South China Antidiabetic Biguanides Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 South China Antidiabetic Biguanides Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 East China Market Performance for Manufacturers
      • 6.2.1 East China Antidiabetic Biguanides Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 East China Antidiabetic Biguanides Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 East China Antidiabetic Biguanides Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 East China Antidiabetic Biguanides Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 Southwest China Market Performance for Manufacturers
      • 6.3.1 Southwest China Antidiabetic Biguanides Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 Southwest China Antidiabetic Biguanides Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 Southwest China Antidiabetic Biguanides Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 Southwest China Antidiabetic Biguanides Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Northeast China Market Performance for Manufacturers
      • 6.4.1 Northeast China Antidiabetic Biguanides Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Northeast China Antidiabetic Biguanides Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Northeast China Antidiabetic Biguanides Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Northeast China Antidiabetic Biguanides Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 North China Market Performance for Manufacturers
      • 6.5.1 North China Antidiabetic Biguanides Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 North China Antidiabetic Biguanides Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 North China Antidiabetic Biguanides Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 North China Antidiabetic Biguanides Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 Central China Market Performance for Manufacturers
      • 6.6.1 Central China Antidiabetic Biguanides Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 Central China Antidiabetic Biguanides Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 Central China Antidiabetic Biguanides Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 Central China Antidiabetic Biguanides Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Northwest China Market Performance for Manufacturers
      • 6.7.1 Northwest China Antidiabetic Biguanides Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Northwest China Antidiabetic Biguanides Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Northwest China Antidiabetic Biguanides Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Northwest China Antidiabetic Biguanides Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration

    7 China Antidiabetic Biguanides Market Performance (Sales Point)

    • 7.1 China Antidiabetic Biguanides Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 China Antidiabetic Biguanides Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 China Antidiabetic Biguanides Price (USD/Unit) by Regions 2013-2018
    • 7.4 China Antidiabetic Biguanides Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 China Antidiabetic Biguanides Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 South China Antidiabetic Biguanides Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 East China Antidiabetic Biguanides Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 Southwest China Antidiabetic Biguanides Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Northeast China Antidiabetic Biguanides Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 North China Antidiabetic Biguanides Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 Central China Antidiabetic Biguanides Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Northwest China Antidiabetic Biguanides Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Hospitals Industry
    • 11.2 Clinics Industry
    • 11.3 Other Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 China Antidiabetic Biguanides Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 China Antidiabetic Biguanides Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 South China Antidiabetic Biguanides Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 East China Antidiabetic Biguanides Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 Southwest China Antidiabetic Biguanides Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Northeast China Antidiabetic Biguanides Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 North China Antidiabetic Biguanides Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Central China Antidiabetic Biguanides Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Northwest China Antidiabetic Biguanides Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Metformin IR Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Metformin SR Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Hospitals Sales and and Growth Rate 2019-2024
      • 12.4.3 Clinics Sales and and Growth Rate 2019-2024
      • 12.4.4 Other Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 China Antidiabetic Biguanides Price (USD/Unit) Trend 2019-2024
      • 12.5.2 China Antidiabetic Biguanides Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split China into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Antidiabetic Biguanides for these regions, from 2012 to 2023 (forecast), including
    South China
    East China
    Southwest China
    Northeast China
    North China
    Central China
    Northwest China

    China Antidiabetic Biguanides market competition by top manufacturers/players, with Antidiabetic Biguanides sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer
    AstraZeneca
    GlaxoSmithKline
    Merck & Co
    Eli Lilly
    Sanofi
    Takeda Pharmaceuticals
    Novo Nordisk
    Servier Laboratories
    Boehringer Ingelheim
    Bristol-Myers Squibb

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Metformin IR
    Metformin SR

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Antidiabetic Biguanides for each application, including
    Hospitals
    Clinics
    Other

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now